PE20040992A1 - Combinaciones sinergicas entre un ligando alfa-2-delta y un inhibidor de pdev - Google Patents

Combinaciones sinergicas entre un ligando alfa-2-delta y un inhibidor de pdev

Info

Publication number
PE20040992A1
PE20040992A1 PE2003000806A PE2003000806A PE20040992A1 PE 20040992 A1 PE20040992 A1 PE 20040992A1 PE 2003000806 A PE2003000806 A PE 2003000806A PE 2003000806 A PE2003000806 A PE 2003000806A PE 20040992 A1 PE20040992 A1 PE 20040992A1
Authority
PE
Peru
Prior art keywords
alpha
pdev inhibitor
delta
synergic combinations
linkage
Prior art date
Application number
PE2003000806A
Other languages
English (en)
Inventor
Mark John Field
Richard Griffith Williams
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of PE20040992A1 publication Critical patent/PE20040992A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Immunology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

SE REFIERE A UNA COMBINACION QUE COMPRENDE: A) UN LIGANDO ALFA-2-DELTA SELECCIONADO ENTRE GABAPENTINA, PREGABALINA, ACIDO [(1R,5R,6S)-6-(AMINOMETIL)BICICLO-[3.2.0]HEPT-6-IL]ACETICO, ENTRE OTROS; B) UN INHIBIDOR DE cGMP PDEV COMPRENDIDO ENTRE SILDENAFILO, TALADAFILO,VARDENAFILO, ENTRE OTROS. SE REFIERE TAMBIEN A UNA COMPOSICION FARMACEUTICA UTIL PARA EL TRATAMIENTO CUURATIVO, PROFILACTICO O PALIATIVO DEL DOLOR
PE2003000806A 2002-08-15 2003-08-12 Combinaciones sinergicas entre un ligando alfa-2-delta y un inhibidor de pdev PE20040992A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0219024.7A GB0219024D0 (en) 2002-08-15 2002-08-15 Synergistic combinations

Publications (1)

Publication Number Publication Date
PE20040992A1 true PE20040992A1 (es) 2004-12-29

Family

ID=9942388

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2003000806A PE20040992A1 (es) 2002-08-15 2003-08-12 Combinaciones sinergicas entre un ligando alfa-2-delta y un inhibidor de pdev

Country Status (40)

Country Link
EP (1) EP1536782B1 (es)
JP (1) JP2006502139A (es)
KR (2) KR20070009746A (es)
CN (1) CN1674884A (es)
AP (1) AP2005003227A0 (es)
AR (1) AR040871A1 (es)
AT (1) ATE359775T1 (es)
AU (1) AU2003249476B2 (es)
BR (1) BR0313484A (es)
CA (1) CA2495433A1 (es)
CR (1) CR7687A (es)
DE (1) DE60313330T2 (es)
DK (1) DK1536782T3 (es)
EA (1) EA007504B1 (es)
EC (1) ECSP055593A (es)
ES (1) ES2285230T3 (es)
GB (1) GB0219024D0 (es)
GE (1) GEP20084366B (es)
GT (1) GT200300173A (es)
HN (1) HN2003000247A (es)
HR (1) HRP20050136A2 (es)
IL (1) IL166415A0 (es)
IS (1) IS7643A (es)
MA (1) MA27381A1 (es)
MX (1) MXPA05001835A (es)
NO (1) NO20050782L (es)
NZ (1) NZ537818A (es)
OA (1) OA12899A (es)
PA (1) PA8577301A1 (es)
PE (1) PE20040992A1 (es)
PL (1) PL375553A1 (es)
PT (1) PT1536782E (es)
RS (1) RS20050078A (es)
SI (1) SI1536782T1 (es)
TN (1) TNSN05042A1 (es)
TW (1) TW200404531A (es)
UA (1) UA77329C2 (es)
UY (1) UY27936A1 (es)
WO (1) WO2004016259A1 (es)
ZA (1) ZA200500369B (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NI200300043A (es) 2002-03-28 2003-11-05 Warner Lambert Co AMINOACIDOS CON AFINIDAD POR LA PROTEINA a2DELTA.
EP1675582A1 (en) * 2003-09-12 2006-07-05 Warner-Lambert Company LLC Combination comprising an alpha-2-delta ligand and an ssri and/or snri for treatment of depression and anxiety disorders
KR100768974B1 (ko) * 2003-09-25 2007-10-22 워너-램버트 캄파니 엘엘씨 알파2델타-단백질에 대한 친화성을 갖는 아미노산
CN1856301A (zh) * 2003-09-25 2006-11-01 沃尼尔·朗伯有限责任公司 治疗性β－氨基酸
GB0405200D0 (en) * 2004-03-08 2004-04-21 Pfizer Ltd Combinations comprising alpha-2-delta ligands
RU2007100355A (ru) * 2004-07-09 2008-07-20 Уорнер-Ламберт Компани Ллс (Us) Получение бета-аминокислот, обладающих аффинностью к альфа-2-дельта-белку
ITMI20041447A1 (it) * 2004-07-20 2004-10-20 Zambon Spa Composizione farmaceutica comprendente gabapentina
US20090227562A1 (en) * 2004-08-10 2009-09-10 Pfizer Inc. Combination of a Selective Noradrenaline Reuptake Unhibitor and a PDEV Inhibitor
CA2578990A1 (en) * 2004-09-07 2006-03-16 Pfizer Inc. Combination of a 5-ht(1) receptor agonist and an alpha-2-delta ligand for the treatment of migraine
WO2006092692A1 (en) * 2005-03-01 2006-09-08 Pfizer Limited Use of combinations of pde7 inhibitors and alpha-2-delty ligands for the treatment of neuropathic pain
MX2009011858A (es) * 2007-04-30 2010-01-14 Adolor Corp Composiciones de (-)-e-10-oh-nt y metodos para su sintesis y uso.
WO2008132589A1 (en) * 2007-05-01 2008-11-06 Pfizer Limited Combinations comprising pregabalin
US20090148532A1 (en) * 2007-12-06 2009-06-11 Venkatesh Gopi M Preparation of controlled release skeletal muscle relaxant dosage forms
TWI531362B (zh) 2008-07-21 2016-05-01 艾爾康股份有限公司 具有治療劑遞送能力之眼科裝置
CA2805371C (en) * 2010-07-30 2017-10-31 Toray Industries, Inc. Therapeutic agent or prophylactic agent for neuropathic pain
US9376438B2 (en) 2011-05-17 2016-06-28 Principia Biopharma, Inc. Pyrazolopyrimidine derivatives as tyrosine kinase inhibitors
SI2710005T1 (sl) 2011-05-17 2017-03-31 Principia Biopharma Inc. Zaviralci tirozinske kinaze
US9580427B2 (en) 2011-05-17 2017-02-28 The Regents Of The University Of California Kinase inhibitors
WO2013084182A1 (en) * 2011-12-08 2013-06-13 Glenmark Pharmaceuticals S.A. Pharmaceutical composition that includes a pde4 enzyme inhibitor and an analgesic agent
DK3181567T3 (da) 2012-09-10 2019-06-11 Principia Biopharma Inc Pyrazolopyrimidinforbindelser som kinasehæmmere
US8957080B2 (en) 2013-04-09 2015-02-17 Principia Biopharma Inc. Tyrosine kinase inhibitors
CN112353806A (zh) 2014-02-21 2021-02-12 普林斯匹亚生物制药公司 Btk抑制剂的盐和固体形式
PT3233103T (pt) 2014-12-18 2021-01-18 Principia Biopharma Inc Tratamento de pênfigo
TW201718572A (zh) 2015-06-24 2017-06-01 普林斯匹亞生物製藥公司 酪胺酸激酶抑制劑
CA3028169A1 (en) 2016-06-29 2018-01-04 Principia Biopharma Inc. Modified release formulations of 2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile
CN114195661B (zh) * 2021-12-21 2023-12-22 苏州楚凯药业有限公司 一种苯磺酸米洛巴林的制备方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE41920E1 (en) * 1996-07-24 2010-11-09 Warner-Lambert Company Llc Isobutylgaba and its derivatives for the treatment of pain
NZ503963A (en) * 1997-12-16 2002-09-27 Warner Lambert Co 1-substituted-1-aminomethyl-cycloalkane derivatives, or gabapentin analogues, preparation and use in the treatment of neurological disorders
HN2000000224A (es) * 1999-10-20 2001-04-11 Warner Lambert Co Aminoacidos biciclicos como agentes farmaceuticos
IL139073A0 (en) * 1999-10-21 2001-11-25 Pfizer Treatment of neuropathy
WO2002019213A2 (en) * 2000-08-30 2002-03-07 Lilly Icos Llc Method for treatment of migraine using pde5 inhibitors
CA2444053C (en) * 2001-04-19 2008-06-17 Warner-Lambert Company Llc Fused bicyclic or tricyclic amino acids

Also Published As

Publication number Publication date
DE60313330D1 (de) 2007-05-31
OA12899A (en) 2006-10-13
ATE359775T1 (de) 2007-05-15
EP1536782A1 (en) 2005-06-08
HN2003000247A (es) 2007-12-14
CA2495433A1 (en) 2004-02-26
PT1536782E (pt) 2007-06-27
KR20050042154A (ko) 2005-05-04
DK1536782T3 (da) 2007-07-30
ECSP055593A (es) 2005-04-18
BR0313484A (pt) 2005-06-21
EA200500207A1 (ru) 2005-08-25
TW200404531A (en) 2004-04-01
UY27936A1 (es) 2004-03-31
AR040871A1 (es) 2005-04-20
GEP20084366B (en) 2008-05-13
KR20070009746A (ko) 2007-01-18
GB0219024D0 (en) 2002-09-25
PL375553A1 (en) 2005-11-28
MXPA05001835A (es) 2005-09-30
EP1536782B1 (en) 2007-04-18
NZ537818A (en) 2007-07-27
AU2003249476A1 (en) 2004-03-03
ES2285230T3 (es) 2007-11-16
AU2003249476B2 (en) 2008-06-26
HRP20050136A2 (en) 2005-06-30
JP2006502139A (ja) 2006-01-19
IS7643A (is) 2005-01-12
SI1536782T1 (sl) 2007-08-31
ZA200500369B (en) 2006-10-25
CR7687A (es) 2005-07-08
CN1674884A (zh) 2005-09-28
AP2005003227A0 (en) 2005-03-31
WO2004016259A1 (en) 2004-02-26
MA27381A1 (fr) 2005-06-01
TNSN05042A1 (fr) 2007-05-14
DE60313330T2 (de) 2008-01-03
GT200300173A (es) 2007-03-29
RS20050078A (en) 2007-09-21
IL166415A0 (en) 2006-01-15
NO20050782L (no) 2005-04-08
UA77329C2 (en) 2006-11-15
EA007504B1 (ru) 2006-10-27
PA8577301A1 (es) 2004-03-10

Similar Documents

Publication Publication Date Title
PE20040992A1 (es) Combinaciones sinergicas entre un ligando alfa-2-delta y un inhibidor de pdev
CL2022000997A1 (es) Métodos para reducir el riesgo de eventos cardiovasculares en un sujeto. (divisional de solicitud 202100645)
PL1718313T3 (pl) Synergiczna przeciwzapalna kompozycja farmaceutyczna do zastosowania w zmniejszaniu stanu zapalnego mediowanego przez PGE2
AR054805A1 (es) Composiciones topicas para el tratamiento de la piel
CR9626A (es) Formas de dosificacion de liberacion retardada oral altamente biodisponible de un o-desmetilvenlafaxin succinato
ES2176343T3 (es) Composiciones sanadoras de tratamiento de heridas causadas por el acne que contienen un piruvano, un antioxidante y una mezcla de acidos grasos.
DE60109938D1 (de) Zusammenstellungen die aktive stilbenoidverbindungen enthalten zur senkung des triglyceridspiegels
WO2006086108A3 (en) Use of inhibitors of soluble epoxide hydrolase to synergize activity of cox and 5-lox inhibitors
DK1296670T3 (da) Terapeutiske fedtsyrekombinationer
AP2001002217A0 (en) 4-IODOPHENYLAMINO BENZHYDROXAMIC ACID OXYGENES ESTERS
BR0211390A (pt) Tratamento de infecções da unha com no
MXPA03010185A (es) Potencialidad de efectos terapeuticos de acidos grasos.
GT200100152A (es) Nueva composicion farmaceutica para el tratamiento de la obesidad.
SI1532974T1 (sl) Zmes, ki vsebuje 6-(3-(1-adamantil)-4-metoksifenil)-2-naftensko kislino, za zdravljenje dermatoloških motenj
AR109263A2 (es) Composición que comprende moxidectina
AU2018280875A1 (en) Solid compositions for oral administration
CO5660280A2 (es) Combinaciones que comprenden ligandos alfa-2-delta
IL160523A0 (en) PHARMACEUTICAL COMPOSITION COMPRISING GABAPENTIN OR AN ANALOGUE THEREOF AND AN alpha-AMINOAMIDE AND ITS ANALGESIC USE
WO2009065395A3 (de) Neue verwendung von omega-3-fettsäure(n)
TW200730190A (en) New combination to treat liver fibrosis
WO2005094385A3 (en) Non-toxic disinfectant containing a isopropyl alcohol and sesame oil composition with lemon oil and menthol
ECSP088242A (es) Combinaciones que comprenden dmxaa para el tratamiento de cancer
ES2194157T3 (es) Composiciones para el cuidado de la piel que contienen un retinoide.
AR034451A1 (es) Microcapsulas para la proteccion frente al mal aliento.
AR058621A1 (es) Metodods para reducir la proteina c reactiva

Legal Events

Date Code Title Description
FC Refusal